Ivana Krajsova Selected Research

Neoplasms (Cancer)

1/2018	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
8/2005	KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ivana Krajsova Research Topics

Disease

10	Melanoma (Melanoma, Malignant) 10/2023 - 08/2005
2	Myalgia 10/2018 - 01/2018
2	Hypertension (High Blood Pressure) 10/2018 - 01/2018
2	Arthralgia (Joint Pain) 10/2018 - 01/2018
2	Neoplasms (Cancer) 01/2018 - 08/2005
1	Skin Neoplasms (Skin Cancer) 01/2020
1	Fever (Fevers) 01/2019
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2015
1	Keratoacanthoma 01/2015

Drug/Important Bio-Agent (IBA)

8	VemurafenibIBA 10/2023 - 04/2014
5	binimetinibIBA 10/2023 - 01/2018
5	encorafenibIBA 10/2023 - 01/2018
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2023 - 01/2018
2	Creatine Kinase (Creatine Phosphokinase)IBA 10/2018 - 01/2018
2	Proto-Oncogene Proteins B-rafIBA 01/2017 - 04/2014
1	Mitogen-Activated Protein KinasesIBA 01/2019
1	dabrafenibIBA 01/2015
1	trametinibIBA 01/2015
1	Dacarbazine (DIC)FDA LinkGeneric 04/2014
1	Imatinib Mesylate (Gleevec)FDA Link 08/2005
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2005

Therapy/Procedure

5	Therapeutics 01/2019 - 08/2005
3	Immunotherapy 01/2020 - 01/2018